KeyBanc's Top 3 MedTech Picks: LIVN, ICUI, and STE

KeyBanc's Top MedTech Selections

KeyBanc Capital Markets has identified LivaNova PLC, ICU Medical Inc, and Steris PLC as leading performers in the medical technology sector. All three companies received an "Overweight" rating, underscoring their strong market positioning and significant growth potential.

Company Highlights and Ratings

LivaNova (LIVN) leads the list with an $81 price target, recognized for its dual focus on cardiopulmonary and neuromodulation technologies. ICU Medical (ICUI) follows with a $175 price target, strengthened by its leadership in infusion therapy and the strategic acquisition of Smiths Medical. Steris (STE) completes the trio with a $291 price target, valued for its comprehensive sterilization and infection prevention solutions for healthcare facilities.

Recent Performance and Developments

Recent positive developments support KeyBanc's analysis. LivaNova is set to benefit from an increase in Medicare reimbursement rates for its VNS Therapy starting in 2026. ICU Medical recently surpassed earnings expectations and raised its full-year guidance. Steris reported strong earnings per share and announced a quarterly dividend, signaling financial stability despite a recent revenue shortfall.

Concluding Analysis

KeyBanc's report suggests these three companies are strategically positioned to address critical needs in healthcare. Their specialized technologies and diverse revenue streams make them standout investments within the competitive MedTech landscape.

FAQ

Q: Which companies did KeyBanc identify as top MedTech picks?
A: KeyBanc highlighted LivaNova PLC (LIVN), ICU Medical Inc (ICUI), and Steris PLC (STE).

Q: What common rating did all three companies receive from KeyBanc?
A: All three companies received an "Overweight" rating.

Source: Investing.com